Global InformationBrivaracetam information
 | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌbrɪvəˈræsətəm/ BRIV-ə-RASS-ə-təm |
| Trade names | Briviact, Nubriveo, Brivajoy |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616027 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Nearly 100% |
| Protein binding | ≤20% |
| Metabolism | Hydrolysis by amidase, CYP2C19-mediated hydroxylation |
| Metabolites | 3 inactive metabolites |
| Elimination half-life | ≈9 hours |
| Excretion | Kidneys (>95%)[4] |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | 100.118.642 |
| Chemical and physical data | |
| Formula | C11H20N2O2 |
| Molar mass | 212.293 g·mol−1 |
| 3D model (JSmol) |
|
| Specific rotation | [α]D −60° |
| Melting point | 72 to 77 °C (162 to 171 °F) |
SMILES
| |
InChI
| |
Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties.[5][6] It is marketed by the pharmaceutical company UCB.[7][8]
A generic version of brivaracetam has been approved by the Food and Drug Administration (FDA) in the United States, but it is not yet available as a generic medication.[9][10]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
- ^ a b Cite error: The named reference
Briviact FDA labelwas invoked but never defined (see the help page). - ^ von Rosenstiel P (January 2007). "Brivaracetam (UCB 34714)". Neurotherapeutics. 4 (1): 84–87. doi:10.1016/j.nurt.2006.11.004. PMC 7479692. PMID 17199019.
- ^ Malawska B, Kulig K (July 2005). "Brivaracetam UCB". Current Opinion in Investigational Drugs. 6 (7): 740–746. PMID 16044671.
- ^ "Briviact Product Page". UCB. Archived from the original on 19 September 2020. Retrieved 1 January 2020.
- ^ "Brivaracetam". DrugBank. Archived from the original on 10 January 2020. Retrieved 1 January 2020.
- ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.